Founded by biotech entrepreneur Romesh Subramanian, Marrow Therapeutics has raised $173 million in Series A and B funding from firms including Scion Life Sciences, venBio, and OrbiMed to develop treatments for sickle cell disease. The company aims to achieve gene therapy-level efficacy while reducing its drawbacks, though this remains to be further validated.
Source:STAT · Read original article
Leave a Reply